Cysticercosis
0
Pipeline Programs
1
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Allergy TherapeuticsUK - West Sussex
2 programsBrain Tissue Swelling and Seizure Activity in Inactive CysticercosisN/A1 trial
Natural History of Treated Neurocysticercosis and Long-Term OutcomesN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Allergy TherapeuticsBrain Tissue Swelling and Seizure Activity in Inactive Cysticercosis
Allergy TherapeuticsNatural History of Treated Neurocysticercosis and Long-Term Outcomes
Clinical Trials (2)
Total enrollment: 506 patients across 2 trials
Brain Tissue Swelling and Seizure Activity in Inactive Cysticercosis
Start: Aug 1999Est. completion: Apr 20126 patients
N/ACompleted
Natural History of Treated Neurocysticercosis and Long-Term Outcomes
Start: Oct 1985500 patients
N/ARecruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 506 patients
1 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.